NSAID 過敏反応の分類と日常診断の更新: WAO 声明
Antonino Romano1, Rocco L Valluzzi2, Emilio Alvarez-Cuesta3
1Oasi Research Institute - IRCCS, Troina, Italy & BIOS S.p.A. Società Benefit, Rome, Italy.
The World Allergy Organization journal
|August 21, 2025
まとめ
この研究は,混合薬および食品関連アレルギーを含む非ステロイド性抗炎症薬 (NSAIDs) に対する過敏反応の分類を更新しています. それは,NSAID誘発性疹/血管腫/アナフィラキシー (NIUAA) の略語を成人に拡張することを提案しています.
科学分野:
- アレルギーと免疫学
- 薬理学について
- 臨床医学
背景:
- 非ステロイド抗炎症薬 (NSAID) に対する過敏反応は,即時または遅延に分類されます.
- 直接的な反応には,NSAIDによって悪化した呼吸器疾患 (N-ERD),NSAIDによって悪化した皮膚疾患 (NECD),NSAIDによって引き起こされた疹/血管腫 (NIUA),および単一のNSAIDによって引き起こされた疹/血管腫/アナフィラキシー (SNIUAA) が含まれる.
- 現在の分類は,複数の臓器系に影響を与える"混合"反応やNSAIDによって悪化した食物アレルギーを完全に扱っていません.
研究 の 目的:
- NSAID過敏反応の分類と診断を更新する.
- 混合反応やNSAIDで悪化した食物アレルギーを含む新しい反応タイプを組み込む.
- NIUAAの略語を成人患者にも適用することを提案する.
主な方法:
- 既存の文献と臨床観察のレビューと統合.
- 各種のNSAID過敏症フェノタイプに対する診断基準の分析
- 改訂された分類枠組みの作成
主要な成果:
- NIUAの基準内で複数の臓器系を含む"混合"反応の特定
- NSAIDによる食物アレルギー (NEFA) とNSAIDによる食物アレルギー (NIFA) の区別
- NIUAAを成人のアナフィラキシー反応に拡張する提案
結論:
- NSAID過敏症の分類は,混合反応とNSAID食品アレルギーを含むように更新する必要があります.
- 正確な患者管理のために 診断基準と用語が改正されなければなりません
- 提案されたNIUAA分類は,成人における重度のNSAID反応の認識と治療を改善することを目的としています.
関連する概念動画
Allergic Reactions
26.4K
Overview
26.4K
Pharmacovigilance
2.0K
Post-marketing surveillance is a critical component of pharmaceutical regulation, often uncovering unanticipated adverse drug reactions (ADRs) once a drug is widely used over an extended period.
This process, termed pharmacovigilance, aims to detect, evaluate, and minimize harmful effects related to medication use. The data collection for pharmacovigilance depends on spontaneous reporting systems, where healthcare professionals or patients voluntarily report suspected ADRs.
In some cases, there...
This process, termed pharmacovigilance, aims to detect, evaluate, and minimize harmful effects related to medication use. The data collection for pharmacovigilance depends on spontaneous reporting systems, where healthcare professionals or patients voluntarily report suspected ADRs.
In some cases, there...
2.0K
Allergic Drug Reactions
1.6K
Allergic reactions related to drugs are hypersensitivity responses driven by the immune system and bear no connection to the drug's therapeutic action. While drugs in isolation do not trigger an immune response, they can interact with endogenous proteins to form antigens. These antigens stimulate lymphocytes to produce antibodies. IgE-type antibodies attach themselves to mast cells. Upon subsequent exposure to the same stimulus, the antigen-antibody interaction is initiated, unleashing...
1.6K
Drug Toxicity: Allergic Reactions
209
Drug-related allergies are immune-mediated responses triggered by the administration of pharmacological agents. These hypersensitivity reactions are classified based on the immune mechanisms involved. The four primary types—Type I, II, III, and IV—are mediated by different immunological pathways and exhibit distinct clinical manifestations.Type I Hypersensitivity/ IgE-Mediated Reactions: Immunoglobulin E (IgE) immediately mediates Type I hypersensitivity reactions. Upon initial...
209
Allergic Reactions: Anaphylaxis
280
Anaphylaxis is a severe, life-threatening hypersensitivity reaction mediated by Immunoglobulin E (IgE) antibodies. When IgE binds to allergens, it triggers the release of mediators– histamine, leukotrienes, and prostaglandins from mast cells and basophils. These mediators cause vasodilation, edema, and inflammation, leading to various symptoms.The primary allergens causing anaphylaxis include food items (e.g., peanuts, shellfish), drugs (e.g., penicillin, asparaginase, corticotropin,...
280
Angina II: Classification
709
Angina, also known as angina pectoris, is a chest pain resulting from diminished blood flow to the heart muscle and is often a symptom of coronary artery disease. Angina presents several variants with distinctive attributes, etiologies, and therapeutic approaches. The main types of angina include stable, unstable, variant (Prinzmetal's), microvascular, intractable, and silent ischemia.Stable angina is caused by atherosclerosis, which leads to the formation of plaques that narrow the coronary...
709


